Open AccessThe Doha declaration in action: An examination of patent law flexibilities in the South African acquired immunodeficiency syndrome epidemic
Author(s) -
Sophie Huddart,
Madlen Nash,
Aya Abdelrasoul,
Inna Bacearnicova,
Kyla Bourque,
Lipi Mishra
Publication year - 2017
Publication title -
journal of health specialties
Language(s) - English
Resource type - Journals
eISSN - 2468-6360
pISSN - 2321-6298
DOI - 10.4103/2468-6360.198802
Subject(s) - declaration , intellectual property , lawsuit , human immunodeficiency virus (hiv) , developing country , human rights , medicine , economic growth , development economics , law , political science , economics , virology
Patent law flexibilities outlined in the Trade-related Aspects of Intellectual Property Rights agreement make it possible for low-income nations to provide affordable essential medicine during health crises. During the rise of the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic in South Africa, multinational pharmaceutical companies challenged the implementation of these flexibilities. In response to this lawsuit, the World Trade Organization enacted the Doha Declaration, an affirmation of the right of low-income nations to import and produce generic versions of patented essential medicines. This case study assesses the Doha Declaration's impact on access to HIV/AIDS treatment in South Africa by examining drug pricing, antiretroviral treatment coverage and drug licensing fees. The declaration ultimately contributed to the decrease in HIV/AIDS treatment costs and the subsequent increase in availability and affordability of life-saving drug regimens